Mass General Brigham May 2 2025 Study data reveal how a specific sequence of cancer therapies can improve outcomes for patients with hard-to-treat lymphomas. Relapsed/refractory (R/R) mature T and natural killer (NK)-cell lymphomas (TNKL) are aggressive blood cancers often resistant to frontline therapies. A team of Mass General Brigham researchers found that patients with these lymphomas had improved survival rates when treated with small molecule inhibitors as second-line therapy, followed by